Literature DB >> 12073111

Modular megaprosthesis for proximal femoral tumors.

I Ilyas1, R Pant, A Kurar, P G Moreau, D A Younge.   

Abstract

Fifteen patients with proximal femoral tumors had resection and limb salvage with an uncemented Kotz (HMRS) megaprosthesis. There were five osteosarcomas, four chondrosarcomas, one hemangioendothelioma, three fibrosarcomas, and two Ewing's sarcomas. The mean follow-up was 6.7 (range 3-10) years. Two patients died of causes not related to the prosthesis. The postoperative Musculoskeletal Tumor Society score (MSTS) score was 19 (range 12-26) for the remaining 13 patients. There were one aseptic loosening, two infections, and one local recurrence. The most frequent complication was hip dislocation at 20%. Reconstruction of proximal femoral tumors with a modular megaprosthesis is a good procedure, but hip instability remains a major problem.

Entities:  

Mesh:

Year:  2002        PMID: 12073111      PMCID: PMC3620889          DOI: 10.1007/s00264-002-0335-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  18 in total

1.  Causes and Frequencies of Reoperations After Endoprosthetic Reconstructions for Extremity Tumor Surgery: A Systematic Review.

Authors:  Patrick Thornley; Matias Vicente; Austin MacDonald; Nathan Evaniew; Michelle Ghert; Roberto Velez
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

2.  Influence of stem design on the primary stability of megaprostheses of the proximal femur.

Authors:  Stefan Kinkel; Jan Dennis Graage; Jan Philippe Kretzer; Eike Jakubowitz; Jan Nadorf
Journal:  Int Orthop       Date:  2013-08-18       Impact factor: 3.075

Review 3.  Megaprosthesis versus Allograft Prosthesis Composite for massive skeletal defects.

Authors:  Deepak Gautam; Rajesh Malhotra
Journal:  J Clin Orthop Trauma       Date:  2017-09-25

4.  Does competing risk analysis give useful information about endoprosthetic survival in extremity osteosarcoma?

Authors:  Reinhard Schuh; Alexandra Kaider; Reinhard Windhager; Philipp T Funovics
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

5.  [The modular endoprosthetic system Munich-Luebeck (MML): potential applications and results in the lower extremities].

Authors:  G von Salis-Soglio; M Ghanem; I Meinecke; M Ellenrieder; H-M Klinger; C Kirchhoff
Journal:  Orthopade       Date:  2010-10       Impact factor: 1.087

Review 6.  High infection rate outcomes in long-bone tumor surgery with endoprosthetic reconstruction in adults: a systematic review.

Authors:  Antonella Racano; Theresa Pazionis; Forough Farrokhyar; Benjamin Deheshi; Michelle Ghert
Journal:  Clin Orthop Relat Res       Date:  2013-02-12       Impact factor: 4.176

7.  Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours--a comparative analysis using the MSTS score, the TESS and the RNL index.

Authors:  P U Tunn; D Pomraenke; U Goerling; P Hohenberger
Journal:  Int Orthop       Date:  2007-08-15       Impact factor: 3.075

8.  Proximal femoral reconstruction with custom mega prosthesis.

Authors:  M Natarajan; J C Bose; G Rajkumar
Journal:  Int Orthop       Date:  2003-03-26       Impact factor: 3.075

9.  Primary rotational stability of various megaprostheses in a biomechanical sawbone model with proximal femoral defects extending to the isthmus.

Authors:  Stefan Kinkel; Jan Nadorf; Jan Dennis Graage; Eike Jakubowitz; Jan Philippe Kretzer
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

10.  Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study.

Authors:  Michelle Ghert; Benjamin Deheshi; Ginger Holt; R Lor Randall; Peter Ferguson; Jay Wunder; Robert Turcotte; Joel Werier; Paul Clarkson; Timothy Damron; Joseph Benevenia; Megan Anderson; Mark Gebhardt; Marc Isler; Sophie Mottard; John Healey; Nathan Evaniew; Antonella Racano; Sheila Sprague; Marilyn Swinton; Dianne Bryant; Lehana Thabane; Gordon Guyatt; Mohit Bhandari
Journal:  BMJ Open       Date:  2012-11-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.